



1 December 2025

CONTROL BIONICS SECURES \$3.25 MILLION PLACEMENT TO ADVANCE COMMERCIAL GROWTH

Control Bionics Limited (ASX: CBL) (“Control Bionics” or “the Company”) is pleased to announce it has successfully completed a private placement of **50,000,000 new fully paid ordinary shares** at an issue price of **\$0.065 per share**, raising **\$3.25 million**. This represents a discount of approximately 6.4% to the 5-day VWAP of CBL shares traded on the ASX up to 28 November 2025.

The placement was completed under the Company’s **Listing Rule 7.1A and 7.1** capacity and was anchored by **Reitham Equity GmbH**, a European private equity investor and long-standing supporter of Control Bionics.

The funds raised will provide additional working capital to accelerate the Company’s commercialisation programs across its core assistive technology products and emerging neurotechnology markets.

Control Bionics CEO and Managing Director, Jeremy Steele, said:

“We are delighted to receive continued support from Reitham Equity as we scale our global footprint. This investment strengthens our balance sheet and enables us to progress key commercial initiatives across assistive communication, rehabilitation, and sports performance. We are committed to delivering innovative neurotechnology solutions that improve independence, quality of life and performance for users worldwide.”

The new shares issued under the placement will rank equally with existing fully paid ordinary shares and are expected to be issued on **5 December 2025**.

This announcement has been authorised for release by the Chairman, **Stephen Rix**.



For further information, please contact:

Investors and Media

Jeremy Steele – CEO and Managing Director
jsteele@controlbionics.com

Brett Crowley - Company Secretary
brettcrowley@controlbionics.com

Investor Relations:

Joe Durak
Executive Director & Founder
Lynx Advisors
joe@lynxadvisors.com.au
+61 414 465 582

For further information visit the website: <https://www.controlbionics.com/>

About Control Bionics:

Control Bionics is a medical device company that more than 20 years experience in the development and use of surface Electromyography (EMG) devices.

About NeuroNode

Our core patented NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as EMG output. This output is then sent wirelessly via the NeuroNode to a personal computer, enabling speech and other computer controlled functions like email and texting. Our technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse, and the NeuroNode acts as like the mouse button. Control Bionics is the only such product to harness three modalities – touch, eye and NeuroNode control – which combined yield unique benefits in terms of the ability of patients to express themselves with significantly faster speed and less fatigue.

About NeuroStrip

Control Bionics is currently commercialising its most recent advancement in its technology, the NeuroStrip. This wearable, miniaturised EMG device provides the business with the opportunity to enter new markets such as health diagnostics, sports performance and rehabilitation to name only a few potential markets.

Control Bionics has a 22% investment in Neuro Elite Athletics to drive rapid growth of their NeuroBounce program in the US and Australia

Control Bionics operates in North America, Australia, Singapore and Japan.